Business Identifier: NO Business Identifier is currently available for this company.
Public Profile: Thermalin Diabetes Inc. is developing a portfolio of insulin analogs to address both the fast-acting and long-acting insulin markets. The company is developing several “insulin analogs” — new proteins engineered to act like insulin in the body. The insulin analogs are heat resistant, unlike the natural hormone, which must be refrigerated. Resistance to heat makes the analogs especially useful in insulin pumps worn outside the body or in locations, like disaster sites, where there is no refrigeration. Thermalin recently signed a licensing agreement with Case that gave the company exclusive worldwide rights to develop a portfolio of more than 100 insulin analogs. The company is in the midst of large-animal tests. Thermalin officials expect to meet with the Food and Drug Administration to plan the regulatory path the company’s products should follow to land on the market. Thermalin expects to file with the FDA an Investigational New Drug (IND) Application, which is required to begin testing a drug on humans, in 2012. Thermalin is aiming to take advantage of the exploding worldwide diabetes market. Worldwide insulin sales are expected to grow from $12 billion to $54 billion over the next 20 years, one of the company’s investors said in March. In 2030, there are expected to be 366 million diabetics worldwide — more than double the amount in 2000, according to the World Health Organization.